Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Vertex Pharma (VRTX) Tops Q4 EPS by 8c, Offers Guidance
January 26, 2022 4:04 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.37, $0.08 better than the analyst estimate of $3.29. Revenue for the quarter came in at $2.07 billion versus the consensus estimate of $2 billion.
GUIDANCE:
Vertex Pharma sees FY2022 revenue of $8.4-8.6 billion, versus the consensus... More
